StimAire

StimAire operates at the intersection of medical devices, sleep medicine, and peripheral neuromodulation. Its initial focus is obstructive sleep apnea, where the company is pursuing an alternative to established approaches such as CPAP, oral appliances, and surgery. The proposed StimAire System uses an injectable neurostimulator activated by a magnetic field, aiming to reduce the procedural burden associated with implanted stimulation systems. The company also describes a broader wearable-and-injectable platform capable of stimulating peripheral nerves at depths of up to 10 centimeters, which could extend its addressable use cases beyond sleep apnea. No distinct peer companies are identified in the available comparable-company information, so direct competitive benchmarking is limited. The main differentiator evident today is the combination of a minimally invasive delivery concept, wireless activation, and a stated effort to avoid CPAP, mouthpieces, and major surgery.

StimAire was founded in Tucson on Sep 1, 2017 and appears to have progressed from early platform development into clinical and regulatory work. The company raised a $2.67 million Series A on Nov 18, 2019, with UAVenture Capital as lead investor and Desert Angels and Sonoran Mavericks also participating. Its patent activity expanded from a wireless neural stimulator filing published in 2020 to additional peripheral nerve stimulation filings published in 2021 and 2022. The company’s product scope has also broadened: while obstructive sleep apnea remains the lead application, its platform is described as capable of stimulating peripheral nerves for other potential indications. The Jul 22, 2024 appointment of Arthur Rascon as COO suggests an effort to add operating infrastructure as development advances. Six current positions are identified, placing StimAire in the small-company stage. Growth therefore appears driven primarily by intellectual-property development, clinical validation, and leadership expansion rather than demonstrated revenue scale.